Stockreport

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for E [Read more]